Quince therapeutics provides business update and reports first quarter 2024 financial results

South san francisco, calif.--(business wire)---- $qncx--quince therapeutics, inc. (nasdaq: qncx), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today provided an update on the company's development pipeline and reported financial results for the first quarter ended march 31, 2024. dirk thye, m.d., quince's chief executive officer and chief medical officer, said, “our primary corporate.
QNCX Ratings Summary
QNCX Quant Ranking